) HealthCare segment recently decided to discontinue the phase
II/III TRUST (TReatment with Unique recombinant rFVIIa STudy)
study on BAY 86-6150. The study was evaluating the efficacy and
safety of the candidate in patients suffering from hemophilia A
or hemophilia B with inhibitors.
Bayer stated that a neutralizing antibody was detected during
the course of the study. Since patient safety was the primary
objective of the study, the company discontinued the BAY 86-6150
trial as a precautionary measure.
Bayer already has Kogenate in its product portfolio for the
treatment of haemophilia. The drug generated around €1.2 billion
in revenues during 2012. Bayer also has BAY 94-9027 (rFVIII
mutein) in its pipeline targeting hemophilia A. The candidate is
currently in phase III development.
We note that companies like
Biogen Idec Inc.
) are also developing therapies targeting the hemophilia
Bayer was recently in the news when it inked a deal to buy
) for $31.00 per share or approximately $1.1 billion in cash.
Bayer intends to launch a public tender soon to acquire all
shares of Conceptus. The transaction is expected to close by
Bayer's impending acquisition of Conceptus will add the Essure
permanent (non-surgical) birth control system to its product
portfolio. We note that Conceptus' Essure procedure was approved
in 2002 in the US and is well accepted in the market.
Bayer, a large cap pharma company, presently carries a Zacks
Rank #4 (Sell). Other large cap pharma companies such as
) currently look more attractive. Abbvie carries a Zacks Rank #2
ABBVIE INC (ABBV): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
CONCEPTUS INC (CPTS): Free Stock Analysis
To read this article on Zacks.com click here.